Zymosan phagocytosis by mouse peritoneal macrophages is increased by apoHDL- and not by intact HDL-covered particles

Autor(es)

M.D.T. Carvalho ^[1] ; V.E. Tobias ^[2] ; C.M.V. Vendrame ^[3] ; A.F.M. Shimabukuro ^[4] ; M. Gidlund ^[5] ; E.C.R. Quintão ^[6]

Afiliação do(s) autor(es)

^[1] Universidade de São Paulo

^[2] Universidade de São Paulo

^[3] Universidade de São Paulo

^[4] Universidade de São Paulo

^[5] Universidade de São Paulo - Brasil

^[6] Universidade de São Paulo

• Tipo de documento: Artigo Científico
• Fonte: Brazilian Journal of Medical and Biological Research; v. 33, n. 3, p. 313-316, 2000-03-00.

Resumo

The uptake of lipids and lipoprotein particles by macrophages undergoes phagocytic activation and the formation of foam cells are key events in atherosclerosis. In this study we determined how intact high density lipoproteins (HDL) and apolipoproteins-HDL (removal of the lipid component from HDL, i.e., apoHDL) influence the phagocytosis of zymosan by mouse peritoneal macrophages. Zymosan particles preincubated together with lipoproteins or alone (control) were incubated with the macrophages. Phagocytosis activity was reported as the percent of macrophages that internalized three or more zymosan particles. HDL co-incubated with zymosan did not influence the over-all uptake of zymosan particles compared to apoHDL, which greatly enhanced the ability of the particle to be phagocytized (P<0.001). Part of this effect might be related to a greater binding of apoHDL to the particles compared to that of HDL (P<0.05). We conclude that this can be a useful method to study the ability of lipoproteins, including modified lipoproteins obtained from subjects with genetic forms of hyperlipidemia, to opsonize particles such as red blood cells and thus to investigate the processes that control the formation of foam cells and the mechanisms of atherogenesis. (AU)

• Processo FAPESP: 99/00158-4 - Desenvolvimento de métodos para detectar a lipoproteína de baixa densidade oxidada (Ox LDL) com vários graus de modificações oxidativas e auto-anticorpos gerados contra a Ox LDL
• Beneficiário: Magnus Ake Gidlund
• Modalidade de apoio: Auxílio à Pesquisa - Regular